Weight Loss Pharmacotherapy

Sep 14, 2024Gastrointestinal endoscopy clinics of North America

Current and Future Medicines for Weight Loss

AI simplified

GLP-1 Therapies on OpenScience ↗PubMed ↗DOI ↗

Abstract

There are currently 5 FDA-approved medications for the treatment of obesity.

The prevalence of obesity is increasing and is a significant health concern.
Surgical options provide more durable weight loss compared to medications or lifestyle changes alone.
Patients frequently experience weight regain and plateaus after surgical interventions.
Multimodal or multihormonal pharmacotherapy may help address challenges associated with weight regain.
Further research is needed to determine the best timing for combining pharmacotherapy with surgical and endoscopic treatments.

AI simplified

The rising prevalence of obesity is of major concern. There are currently 5 Food and Drug Administration-approved medications for the treatment of obesity: orlistat, phentermine/topiramate, naltrexone/bupropion, liraglutide 3.0 mg, and semaglutide 2.4 mg. Surgical options such as bariatric surgery and endoscopic surgery induce more durable weight loss than pharmacotherapy or lifestyle interventions alone. However, patients often experience weight regain and weight loss plateau after surgery. The addition of multimodal or multihormonal pharmacotherapy is a promising tool to address these challenges. The optimal timing of obesity pharmacotherapy with surgical and endoscopic interventions requires further investigation.

Full Text

Full text is available at the source.

View full text (XML) ↗View full text ↗

Weight Loss Pharmacotherapy

Abstract

Full Text

You found one interesting study. We’ll send the next 7.

what lands in your inbox each week:

Recent issues from the glp-1 therapies brief

Abstract

Full Text

Related papers

You found one interesting study. We’ll send the next 7.

what lands in your inbox each week:

Recent issues from the glp-1 therapies brief